MKC:NYSEMcCormick & Company, Incorporated Analysis
Data as of 2026-06-12 - not real-time
$49.23
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
McCormick & Company (MKC) trades around $49.23, well above its DCF-derived fair value of $18.42, signaling a substantial overvaluation despite a low trailing P/E of 8.07 and a robust dividend yield of 3.9%. The company posted a 16.7% revenue growth year‑over‑year, healthy gross (38.2%) and operating margins (14.3%), and a solid free cash flow generation of $373 M, supporting its Buy analyst consensus and dividend sustainability. However, the price sits below its 20‑day (47.24) and 50‑day (49.24) SMAs and far above the 200‑day SMA (61.48), with the stock hovering near the identified support at $45.53 and facing resistance near $50.15, indicating a bearish technical backdrop.
The 30‑day volatility of ~26% and a negative beta (‑0.19) reflect heightened price swings yet low market correlation, while the consumer‑defensive sector provides a low‑risk backdrop. Increasing volume suggests renewed trader interest, but the combination of overvaluation, bearish trend direction, and elevated short‑term volatility warrants caution, making a near‑term sell stance prudent while the strong fundamentals justify a medium‑term buy outlook.
The 30‑day volatility of ~26% and a negative beta (‑0.19) reflect heightened price swings yet low market correlation, while the consumer‑defensive sector provides a low‑risk backdrop. Increasing volume suggests renewed trader interest, but the combination of overvaluation, bearish trend direction, and elevated short‑term volatility warrants caution, making a near‑term sell stance prudent while the strong fundamentals justify a medium‑term buy outlook.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below short‑term moving averages and near support level
- High short‑term volatility (~26%)
- Significant overvaluation versus DCF fair value
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth (16.7%) and solid margins
- Sustainable dividend with low payout ratio (30%)
- Analyst consensus buy and attractive valuation multiples (P/E 8)
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Defensive consumer staple positioning with global brand portfolio
- Consistent dividend aristocrat status and cash flow generation
- Persistent valuation gap suggesting price may need correction
Key Metrics & Analysis
Financial Health
Revenue Growth16.70%
Profit Margin23.12%
P/E Ratio8.1
ROE25.35%
ROA4.88%
Debt/Equity65.16
P/B Ratio1.9
Op. Cash Flow$897.6M
Free Cash Flow$372.8M
Technical Analysis
TrendBearish
RSI56.2
Support$45.53
Resistance$50.15
MA 20$47.24
MA 50$49.24
MA 200$61.48
MACDBullish
VolumeIncreasing
Fear & Greed Index87.77
Valuation
Fair Value$18.42
Target Price$61.31
Upside/Downside24.53%
GradeOvervalued
TypeBlend
Dividend Yield3.90%
Risk Assessment
Beta-0.19
Volatility25.89%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.